Drug intelligence / Profile preview

gabapentin + acetaminophen

Development stage
Unknown
Lead developer
Inova Health
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

This is an investigational multimodal analgesic regimen developed by **Inova Health Care Services** for the management of postoperative pain, specifically in patients undergoing coronary artery bypass graft (CABG) surgery. The regimen consists of oral **gabapentin**, which modulates the alpha-2-delta subunit of voltage-gated calcium channels to inhibit the release of excitatory neurotransmitters, and intravenous **acetaminophen**, which provides analgesia through the inhibition of prostaglandin synthesis in the central nervous system. This combination is being evaluated as an opioid-sparing approach (the **INOVAOPIOID** study) to reduce the incidence of opioid-related adverse events, such as postoperative ileus and respiratory complications, while providing effective pain relief compared to standard opioid-based protocols.

Other names
oral gabapentin and intravenous acetaminophenmultimodal pain regimenGabapentin + IV Acetaminophen
02

Targets

CACNA2D2 (α2δ-2)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)

Beyond the preview

Go deeper on gabapentin + acetaminophen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gabapentin + acetaminophen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call